John Hadden Net Worth

The estimated Net Worth of John Hadden is at least $148 dollars as of 14 December 2020. John Hadden owns over 1,000 units of PLx Pharma stock worth over $148 and over the last 8 years he sold PLXP stock worth over $0. In addition, he makes $0 as Director at PLx Pharma.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

John Hadden PLXP stock SEC Form 4 insiders trading

John has made over 2 trades of the PLx Pharma stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 1,000 units of PLXP stock worth $5,450 on 14 December 2020.

The largest trade he's ever made was buying 1,000 units of PLx Pharma stock on 14 December 2020 worth over $5,450. On average, John trades about 214 units every 3 days since 2017. As of 14 December 2020 he still owns at least 3,690 units of PLx Pharma stock.

You can see the complete history of John Hadden stock trades at the bottom of the page.

John Hadden biography

John Hadden is the Director at PLx Pharma.

What's John Hadden's mailing address?

John's mailing address filed with the SEC is 8285 El Rio St #130, Houston, TX 77054, USA.

Insiders trading at PLx Pharma

Over the last 8 years, insiders at PLx Pharma have traded over $0 worth of PLx Pharma stock and bought 841,160 units worth $2,548,334 . The most active insiders traders include West Asset Management Llc Park, Michael J Valentino, eDavid Emerson Jorden. On average, PLx Pharma executives and independent directors trade stock every 124 days with the average trade being worth of $2,403. The most recent stock trade was executed by Natasha Giordano on 15 March 2022, trading 4,100 units of PLXP stock currently worth $14,965.

What does PLx Pharma do?

PLx Pharma Inc. is a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with aspirin and ibuprofen, and potentially other drugs.

Complete history of John Hadden stock trades at PLx Pharma

PLx Pharma executives and stock owners

PLx Pharma executives and other stock owners filed with the SEC include:

• Natasha Giordano,
  CEO, Pres & Director
• Robert Shawah,
  Chief Accounting Officer, Treasurer
• Rita M. O'Connor CPA, CPA,
  CFO and Head of Manufacturing & Supply Chain
• Michael J. Valentino,
  Exec. Chairman
• Michael Valentino,
  Director
• John Hadden,
  Director
• Natasha Giordano,
  Director
• Robert Casale,
  Director
• Kirk Calhoun,
  Director
• Anthony Bartsh,
  Director
• Gary Balkema,
  Director
• Tom Long,
  Vice President - Manufacturing & Technical Operations
• Steven Valentino,
  Vice President - Trade Sales
• Rita O Connor,
  Chief Financial Officer
• Harris Kaplan M.B.A., MBA,
  Member of Chief Exec. Officer Advisory Group
• Janet M. Barth,
  VP of Investor Relations & Corp. Communications
• Harris Kaplan MBA,
  Member of Chief Exec. Officer Advisory Group
• Charles Edmund Sheedy C.F.A., CFA,
  Member of Chief Exec. Officer Advisory Group
• Patrick M. Lonergan,
  Member of Chief Exec. Officer Advisory Group
• Nicole Godino,
  National Sales Director
• Joanne Cotignola,
  VP of Marketing
• Ronald R. Zimmerman,
  Founder & Sr. Advisor
• Efthymios Deliargyris,
  Chief Medical Officer
• West Asset Management Llc Park,
  10% owner
• David Emerson Jorden,
  Acting Chief Financial Officer
• Gary L Mossman,
  Chief Operating Officer
• David P Luci,
  Director